Detalhe da pesquisa
1.
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS).
Clin Infect Dis
; 75(11): 1971-1979, 2022 11 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35438137
2.
Effectiveness of primary series, first, and second booster vaccination of monovalent mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections and severe diseases during the SARS-CoV-2 omicron BA.5 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Expert Rev Vaccines
; 23(1): 213-225, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288980
3.
Effectiveness of mRNA COVID-19 vaccines against symptomatic SARS-CoV-2 infections during the SARS-CoV-2 Omicron BA.1 and BA.2 epidemic in Japan: vaccine effectiveness real-time surveillance for SARS-CoV-2 (VERSUS).
Expert Rev Vaccines
; 22(1): 288-298, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36883371
4.
Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses.
Hepatogastroenterology
; 50(52): 961-6, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-12845959
5.
[Novel treatment with oncolytic herpes simplex virus, 'HF10' against breast cancer].
Nihon Rinsho
; 62(5): 987-93, 2004 May.
Artigo
em Japonês
| MEDLINE | ID: mdl-15148832
6.
Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
Ann Surg Oncol
; 13(8): 1078-84, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16865590
7.
Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10.
J Surg Oncol
; 85(1): 42-7, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14696086